Dataset Information


Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

ABSTRACT: Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from MHC restriction and thus breaking one of the barriers to more widespread application of cellular therapy. Similar to treatment strategies employing monoclonal antibodies, T cells expressing CARs are highly targeted, but additionally offer the potential benefits of active trafficking to tumor sites, in vivo expansion and long-term persistence. Furthermore, gene transfer allows the introduction of countermeasures to tumor immune evasion and of safety mechanisms.The basic structure of so-called first and later generation CARs and their potential advantages over other immune therapy systems. How these molecules can be grafted into immune cells (including retroviral and non-retroviral transduction methods) and strategies to improve the in vivo persistence and function of immune cells expressing CARs. Examples of tumor-associated antigens that have been targeted in preclinical models and clinical experience with these modified cells. Safety issues surrounding CAR gene transfer into T cells and potential solutions to them.Because of recent advances in immunology, genetics and cell processing, CAR-modified T cells will likely play an increasing role in the cellular therapy of cancer, chronic infections and autoimmune disorders.


PROVIDER: S-EPMC3107373 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC4106238 | BioStudies
2016-01-01 | S-EPMC4816271 | BioStudies
2020-01-01 | S-EPMC7194322 | BioStudies
1000-01-01 | S-EPMC5675441 | BioStudies
2013-01-01 | S-EPMC3746289 | BioStudies
2017-01-01 | S-EPMC5746871 | BioStudies
2018-01-01 | S-EPMC5986730 | BioStudies
2019-01-01 | S-EPMC6325111 | BioStudies
2010-01-01 | S-EPMC3245576 | BioStudies
2019-01-01 | S-EPMC6745938 | BioStudies